arrow
N

Nicola Zerbinati

department of medicine and technological innovation
H指数:26
被引数:3,203

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HPV DNA negativity following AHCC or nonavalent vaccination or their combination in women with persistent HPV infection without HSIL

HPV DNA阴性在持续HPV感染但无HSIL的女性中,接受AHCC或九价疫苗接种或其联合治疗后的表现

2026-08-290
OAAI
Italian Expert Consensus on Poly(ethylene glycol) Diglycidyl Ether-Crosslinked Hyaluronic Acid Hydrogels for Facial Aesthetics: Product Selection, Injection Techniques, and Safety

意大利专家共识:聚乙二醇二缩水甘油醚交联透明质酸水凝胶在面部美学中的应用——产品选择、注射技术及安全性

2026-03-120
OAAI
Assessment of Safety and Tissue Integration of PEGDE-Based Hyaluronic Acid Filler for Severe Nasolabial Folds: A Prospective Observational Study with Biophysical and Ultrasound Evaluation

评估PEGDE基透明质酸填充剂用于严重鼻唇沟纹的安全性及组织相容性:一项结合生物物理学和超声评估的前瞻性观察研究

2026-03-040
OAAI
Gut Microbiota and Autism: Unlocking Connections

Biagioli, V.; Matera, M.; Cavecchia, I.; Di Pierro, F.; Zerbinati, N.; Striano, P. 肠道微生物组与自闭症:解锁关联。Nutrients 2025, 17, 3706. [Google Scholar] [CrossRef]

2026-03-030
OAAI
Real-world comparison of IL-23 inhibitors in moderate-to-severe plaque psoriasis: a focus on super responders-IL PSO (Italian landscape Psoriasis)

IL-23抑制剂在轻至重度斑块状银屑病中的真实世界比较:重点关注超应答者——IL PSO(意大利银屑病全景)

2026-02-170
PRE
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis)

IL-23抑制剂在影响高影响区域银屑病中的真实世界疗效:Tildrakizumab 200 mg、Risankizumab和Guselkumab的间接比较—IL PSO(意大利银屑病景观研究)

2026-02-160
OAAI
Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study

特应性皮炎患者接受度普利尤单抗或特拉利尤单抗治疗时的银屑病和血清阴性脊柱关节病:一项多中心观察性研究

2026-02-011
PRE
Study to evaluate the safety and tolerability of Streptococcus salivarius eK12; a genetically modified strain derived from the oral probiotic S. salivarius K12: Results from a randomized; double-blind; placebo-controlled; parallel-group clinical trial

研究评估链球菌salivarius eK12的安全性及耐受性;一种源自口腔益生菌S. salivarius K12的基因改造菌株:一项随机、双盲、安慰剂对照、平行组临床试验的结果

2025-12-080
OAAI